

Biotin Human OX40 (CD134) Protein (C-Fc-Avi)

Catalog Number:	818103, 818104
Size:	25 ug, 100 ug
Target Name:	TNFRSF4, OX40, CD134, OX40L receptor
Regulatory Status:	RUO


PRODUCT DETAILS

Application:	ELISA, BLI
Format:	Liquid, Biotinylated
Expression Host:	CHO
Species:	Human
Sources:	Recombinant Human OX40 (Lue29-Ala216) with C-terminus Fc-Avi-tag is expressed in CHO cell. This protein was site-specifically labeled with Biotin by BirA ligase.
Accession Number:	P43489
Molecular Weight:	The protein has a predicted molecular weight of 48.5 kDa. Under DTT-reducing conditions, it migrates at approximately 65 kDa on SDS-PAGE.
Affinity Tag:	C-Fc-Avi
Purity:	>95% based on SDS-PAGE under reducing condition
Formulation:	1xPBS buffer, pH7.4, 0.22 µm filtered
Endotoxin level:	Not tested
Protein Concentration:	25µg size is bottled at 0.2mg/mL concentration. 100 µg size is supplied at a lot-specific concentration.
Storage and Handling:	Briefly centrifuge the vial upon receipt. An unopened vial can be stored at 4°C for up to 2 weeks, or at -20°C or below for up to six months. The protein may be further diluted to 0.1 mg/mL using 0.22 µm-filtered PBS buffer (pH 7.4). For long-term storage, the diluted stock solution should be aliquoted and stored at ≤ -70°C to minimize freeze-thaw cycles. If additional dilution is required, carrier proteins such as FBS or BSA should be added to maintain protein stability.

BACKGROUND INFORMATION

OX40 (CD134) and its ligand OX40L (CD252), both part of the TNF receptor superfamily, play a key role in immune regulation. Their interaction is essential for T-cell expansion, survival, and cytokine production, influencing T cells, antigen-presenting cells, NK cells, and NKT cells. OX40-OX40L signaling helps break immune tolerance in malignancies, promoting antitumor immunity, and is also involved in the development of inflammatory and autoimmune diseases. Due to these regulatory effects, the OX40-OX40L pathway is a promising target for therapeutic interventions in both cancer and infectious diseases, with OX40 stimulation showing potential for therapeutic immunization strategies.

PRODUCT DATA



Human OX40 (C-Fc-Avi) was biotinylated in vitro using BirA ligase. SDS-PAGE analysis under reducing (P+) and non-reducing (P-) conditions shows the protein has a purity greater than 95%. A gel shift assay using co-incubation with streptavidin indicates that the biotinylation efficiency of Human OX40 protein exceeds 90%.